Table 1. T8senhigh status is not associated with specific CMV-protein immunization.
Pan-virus serological profile was assessed in sera of 176 patients with aNSCLC. Protein reactivity was positive if at least one peptide was recognized (enrichment fold change > 1). In CMV+ patients (n = 117), proportions of CD8+ senescent T cells were analyzed according to reactivity against 29 proteins with at least 20% of protein-seropositive patients and 20% of protein-seronegative patients, by Mann-Whitney test. Proportions of protein-seropositive patients were then compared between T8senhigh and T8senlow patients by Fisher’s test. T8sen, senescent CD8+ T cells defined by the proportion of CD28−CD57+KLRG1+ T cells among CD8+; US, unique short; UL, unique long. Bolded values, P < 0.05.
| Protein | Number and [proportion] of protein-seropositive patients | Median CD8+ senescent T cell proportions | Proportions of protein-seropositive patients | ||||
|---|---|---|---|---|---|---|---|
| Seronegative patients | Seropositive patients | P value | In T8senlow patients | In T8senhigh patients | P value | ||
| Tegument protein IRS1 | 25 [21.37%] | 23.895 | 32.81 | 0.0081 | 18.18 | 31.03 | 0.1906 |
| gB (fragment) | 81 [69.23%] | 22.035 | 27.27 | 0.0208 | 63.64 | 86.21 | 0.0352 |
| Glycoprotein gp58 (fragment) | 77 [65.81%] | 22.215 | 27.27 | 0.0275 | 61.36 | 79.31 | 0.1132 |
| Membrane protein US20 | 54 [46.15%] | 24.31 | 29.35 | 0.0401 | 42.05 | 58.62 | 0.1371 |
| Transmembrane protein HWLF3 | 39 [33.33%] | 24.885 | 31.52 | 0.0528 | 30.68 | 41.38 | 0.3642 |
| Capsid protein P40 | 40 [34.19%] | 25.68 | 28.435 | 0.1208 | 31.82 | 41.38 | 0.3727 |
| gB amino part of (fragment) | 33 [28.21%] | 25.225 | 30.88 | 0.1284 | 26.14 | 34.48 | 0.4759 |
| Tegument protein UL83 (pp65) | 56 [47.86%] | 24.87 | 31.49 | 0.1429 | 44.32 | 58.62 | 0.2038 |
| UL139 | 72 [61.54%] | 21.42 | 26.99 | 0.1681 | 59.09 | 68.97 | 0.3858 |
| Matrix phosphoprotein (fragment) | 56 [47.86%] | 24.81 | 28.435 | 0.2311 | 45.45 | 55.17 | 0.3975 |
| IE19 | 50 [42.74%] | 25.58 | 27.41 | 0.2977 | 43.18 | 41.38 | 1.0000 |
| Protein IRL10 | 38 [32.48%] | 25.72 | 26.62 | 0.2988 | 29.55 | 41.38 | 0.2591 |
| UL36 | 32 [27.35%] | 26.06 | 26.38 | 0.4374 | 25.00 | 34.48 | 0.3431 |
| UL132 (fragment) | 58 [49.57%] | 26.26 | 25.89 | 0.5597 | 46.59 | 58.62 | 0.2904 |
| Protein ICP36 | 45 [38.46%] | 25.65 | 27.74 | 0.5658 | 38.64 | 37.93 | 1.0000 |
| G-protein coupled receptor homolog US27 | 27 [23.08%] | 26.99 | 25.68 | 0.6070 | 22.73 | 24.14 | 1.0000 |
| Immediate-early protein 1 (IE1) | 59 [50.43%] | 25.99 | 26.06 | 0.6826 | 51.14 | 48.28 | 0.8328 |
| Envelope glycoprotein UL132 | 69 [58.97%] | 25.265 | 27.08 | 0.7229 | 56.82 | 65.52 | 0.5150 |
| Tegument protein UL11 homolog (pp28) | 92 [78.63%] | 27.08 | 25.7 | 0.7521 | 78.41 | 79.31 | 1.0000 |
| Viral transcription factor IE2 (UL122) | 75 [64.1%] | 27.225 | 24.87 | 0.7611 | 63.64 | 65.52 | 1.0000 |
| UL132B | 63 [53.85%] | 26.58 | 25.68 | 0.7678 | 51.14 | 62.07 | 0.3913 |
| UL25 (pp85) | 33 [28.21%] | 25.99 | 26.06 | 0.7852 | 27.27 | 31.03 | 0.8123 |
| Tegument protein UL82 (pp71) | 33 [28.21%] | 26.58 | 25.58 | 0.8180 | 29.55 | 24.14 | 0.6413 |
| IE9 | 47 [40.17%] | 26.58 | 25.68 | 0.8218 | 40.91 | 37.93 | 0.8300 |
| Immediate-early protein (fragment) | 44 [37.61%] | 26.26 | 25.87 | 0.8373 | 37.50 | 37.93 | 1.0000 |
| Immediate-early protein 2 (IE2) | 80 [68.38%] | 27.08 | 25.32 | 0.8489 | 67.05 | 72.41 | 0.6515 |
| Early phosphoprotein p84 | 25 [21.37%] | 26.16 | 25.68 | 0.9021 | 21.59 | 20.69 | 1.0000 |
| Membrane protein RL12 | 40 [34.19%] | 25.72 | 26.48 | 0.9199 | 35.23 | 31.03 | 0.8222 |
| Tegument protein UL71 | 67 [57.26%] | 27.6 | 24.96 | 0.9232 | 56.82 | 58.62 | 1.0000 |